Longevity & Bioregulators · Source-reviewed dossier
PNC-27
Source-Reviewed Research Dossier
PNC-27 is a p53-derived membrane-active research peptide designed to interact with HDM-2 expressed on selected cancer-cell membranes. Current evidence remains laboratory and preclinical and does not support a human cancer-treatment claim.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
- Product type
- Peptide research compound
- Catalog family
- PNC-27
- Research category
- Longevity & Bioregulators
- Evidence status
- Cell and preclinical evidence; no established human clinical efficacy
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- p53-derived anticancer research peptideCatalog-family identity
- Evidence scope
- Cell and preclinical evidence; no established human clinical efficacyDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
How PNC-27 is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about PNC-27
Reported outcomes are paired with their experimental model and evidence boundary.
Membrane interaction and cell death were examined
A 2024 study evaluated PNC-27 interactions and cytotoxicity in experimental cancer systems.
Laboratory cytotoxicity does not establish a therapeutic window in humans.
Read the primary studyAntitumor activity was tested outside controlled human trials
A 2025 report investigated PNC-27 in additional experimental tumor models.
Model-specific antitumor findings require independent clinical validation.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for PNC10
Product specification
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Quality documentation
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Membrane interaction and cell death were examined
Laboratory cytotoxicity does not establish a therapeutic window in humans.
View primary recordAntitumor activity was tested outside controlled human trials
Model-specific antitumor findings require independent clinical validation.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Cancer-cell study
PNC-27 membrane-associated anticancer research
Preclinical study. 2024. PMID 38802154.
-
02
Preclinical study
PNC-27 experimental antitumor study
Preclinical study. 2025. PMID 40750238.
PNC-27 questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What is PNC-27?
PNC-27 is a p53-derived membrane-active research peptide designed to interact with HDM-2 expressed on selected cancer-cell membranes. Current evidence remains laboratory and preclinical and does not support a human cancer-treatment claim.
What evidence is available for PNC-27?
Recent records continue to be preclinical; controlled human trial evidence was not identified.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should PNC-27 be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: PNC10 · 10 mg × 10 vials